| Identification | Back Directory | [Name]
(S)-Lansoprazole | [CAS]
138530-95-7 | [Synonyms]
S-Isomer: 008
(S)-Lansoprazole
Levolansoprazole
Lansoprazole S-Isome
Lansoprazole S-IsoMer
Lansoprazole Impurity 15
Dexlansoprazole Impurity 8
levogyration lansoprazole Impurity 10
Lansoprazole S-Isomer/ Levolansoprazole
2-[(S)-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-
(S)-2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
2-[(S)-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
1H-Benzimidazole, 2-[(S)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-
1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-, (S)-
(S)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
1H-Benzimidazole, 2-[(S)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) | [Molecular Formula]
C16H14F3N3O2S | [MDL Number]
MFCD16294176 | [MOL File]
138530-95-7.mol | [Molecular Weight]
369.36 |
| Chemical Properties | Back Directory | [Melting point ]
60-65°C | [Boiling point ]
555.8±60.0 °C(Predicted) | [density ]
1.50±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
9.56±0.10(Predicted) | [color ]
Beige to Light Brown |
| Hazard Information | Back Directory | [Description]
(S)-Lansoprazole is a proton pump inhibitor that irreversibly inhibits H+/K+-stimulated ATPase pumps in parietal cells (IC50 = 5.2 μM), inhibiting gastric acid secretion and increasing intragastric pH. It also inhibits acid formation in isolated canine parietal cells (IC50 = 82 μM). (S)-Lansoprazole is an enantiomerically pure form of lansoprazole . Both (S)- and (R)-lansoprazole are pharmacologically active with similar potencies. | [Chemical Properties]
Light Brown Solid | [Uses]
The S-enantiomer of Lansoprazole; a gastric proton pump inhibitor. An antiulcerative | [in vivo]
Lansoprazole (20-40 mg/kg) treatment significantly attenuated STZ and HFD -induced memory deficits, biochemical and histopathological alterations[3].
Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced increase in AChE activity[3].
Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced rise in brain MPO level[3].
Further HFD mice treated with lansoprazole (20 mg/kg and 40 mg/kg, p.o.) shows a marked decrease in the body weight in comparison to the control animals[3].
| [storage]
Store at -20°C | [References]
[1] SCHUBERT M L. Pharmacotherapy for acid/peptic disorders.[J]. Yale Journal of Biology and Medicine, 1996, 69 2: 197-201.
|
|
|